Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AL-335 in Renal Impairment
NCT02894905Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adafosbuvir in hepatitis C (HCV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Concentration, Area Under the Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Sep 2016; status: completed.
02
Drugs
adafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02894905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894905.